European Patent Office

T 1442/19 vom 05.07.2022

Europäischer Rechtsprechungsidentifikator
ECLI:EP:BA:2022:T144219.20220705
Datum der Entscheidung
5. Juli 2022
Aktenzeichen
T 1442/19
Antrag auf Überprüfung von
-
Anmeldenummer
12167589.6
Verfahrenssprache
Englisch
Verteilung
Nicht verteilt (D)
Amtsblattfassungen
Keine AB-Links gefunden
Weitere Entscheidungen für diese Akte
-
Zusammenfassungen für diese Entscheidung
-
Bezeichnung der Anmeldung
Modulators of pharmacokinetic properties of therapeutics
Name des Antragstellers
GILEAD SCIENCES, INC.
Name des Einsprechenden
Teva Pharmaceutical Industries Ltd.
Cooke, Richard
Kammer
3.3.02
Leitsatz
-
Relevante Rechtsnormen
European Patent Convention Art 56European Patent Convention Art 76(1)Rules of procedure of the Boards of Appeal Art 12(4)
Schlagwörter
Divisional application - added subject-matter
Inventive step
Late-filed request - submitted with the reply to the statements of grounds of appeal
Orientierungssatz
Extension of subject-matter: selection from an indication of equally preferred items (e.g. formed by several independent claims) disclosed in the application as filed (see point 2.4.1 of the Reasons)
Zitierende Akten
T 2004/20T 1271/23

Order

For these reasons it is decided that:

1. The decision under appeal is set aside.

2. The case is remitted to the opposition division with the order to maintain the patent in amended form with the following claims and a description to be adapted thereto: claims 1 and 2 of auxiliary request 2 filed with the reply to the statements of grounds of appeal.